Neoadjuvant therapy
Clinical trials for Neoadjuvant therapy explained in plain language.
Never miss a new study
Get alerted when new Neoadjuvant therapy trials appear
Sign up with your email to follow new studies for Neoadjuvant therapy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can an oral HER2 drug boost Chemo's punch in HER2-Low breast cancer?
Disease control OngoingResearchers are testing whether adding pyrotinib, an oral drug that targets HER2-family proteins, to standard chemotherapy helps shrink HER2-low, hormone receptor-positive breast cancer before surgery. The trial enrolls about 48 women with early or locally advanced disease. Every…
Matched conditions: NEOADJUVANT THERAPY
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can immunotherapy before surgery shrink head and neck tumors?
Disease control OngoingResearchers are testing whether adding the immunotherapy drug toripalimab to standard chemotherapy (gemcitabine and cisplatin) before surgery can help patients with locally advanced head and neck squamous cell carcinoma. The trial enrolls about 20 adults whose tumors can be remov…
Matched conditions: NEOADJUVANT THERAPY
Phase 1 • Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
Disease control By invitation onlyThis trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to se…
Matched conditions: NEOADJUVANT THERAPY
Phase 2/3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Modified herpes virus joins forces with immunotherapy to attack head and neck tumors
Disease control OngoingThis study tests a combination of three treatments—immunotherapy (tislelizumab), targeted therapy (afatinib), and a modified herpes virus (lysogenic HSV)—given before surgery for head and neck squamous cell carcinoma. The goal is to see if this approach safely shrinks tumors and …
Matched conditions: NEOADJUVANT THERAPY
Phase 1/2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Lung cancer hope: drug combo before surgery shows promise
Disease control OngoingThis study tests whether giving the immunotherapy drug serplulimab together with chemotherapy before surgery can help shrink non-small cell lung cancer and improve outcomes. About 36 adults with stage IIA to IIIB lung cancer will receive the combination, then have surgery to remo…
Matched conditions: NEOADJUVANT THERAPY
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could chemo before surgery beat cancer better?
Disease control OngoingThis study compares two treatments for a rare type of urinary tract cancer. One group gets chemotherapy before surgery, the other has surgery alone. The goal is to see if chemo helps shrink the tumor and improve long-term outcomes. About 120 adults with high-risk, non-spread canc…
Matched conditions: NEOADJUVANT THERAPY
Phase 2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Immunotherapy plus chemo shows promise against tough throat cancer
Disease control OngoingThis phase 2 trial tests whether adding a PD-1 inhibitor (a type of immunotherapy) to standard chemotherapy before radiation can improve outcomes for people with advanced nasopharyngeal carcinoma. About 150 participants will receive either the combination or chemotherapy alone, f…
Matched conditions: NEOADJUVANT THERAPY
Phase 2 • Sponsor: Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Promising combo aims to shrink esophageal tumors before surgery
Disease control OngoingThis study tests whether adding the drug serplulimab to standard chemotherapy before surgery can help people with a certain type of esophageal cancer. The goal is to shrink tumors more effectively and lower the chance of cancer coming back. About 48 adults with stage II to IVA es…
Matched conditions: NEOADJUVANT THERAPY
Phase 2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Immunotherapy-Chemo cocktail targets tough colon cancer before surgery
Disease control OngoingThis phase 2 trial is testing whether adding the immunotherapy drug tislelizumab to standard chemotherapy (oxaliplatin and capecitabine) before surgery can help shrink tumors in people with a specific type of locally advanced colon cancer called microsatellite stable (MSS). About…
Matched conditions: NEOADJUVANT THERAPY
Phase 2 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC